THE TROPONIN PROGNOSTIC CAPABILITY IN DIAGNOSING CARDIOTOXICITY DURING CHEMOTHERAPY WITH ANTHRACYCLINES AND MONOCLONAL ANTIBODIES IN BREAST CANCER PATIENTS
Introduction. Breast cancer is sensitive to some schemes of chemotherapy known to be aggressive towards the cardiovascular system. There is anthracycline-mediated irreversible cardiotoxicity of the first type and trastuzumab-mediated reversible cardiotoxicity of the second type. The use of serum biomarkers capable of detecting myocardial injury before symptoms appear is an alternative approach to early diagnosis of the chemotherapy cardiotoxic complications.
Aim: analyze the prognostic value of troponin for the early detection of cardiotoxic complications caused by anthracycline and/or trastuzumab in breast cancer patients.
Search strategy: The search was carried out across the databases Pubmed, Web of Science, Scopus, e-LIBRARY. Criteria for inclusion in the review were: randomized controlled trials and prospective studies dated 2010–2020. The keywords were used according to the following sections: pathology: "breast cancer", "breast"; treatment: «anthracyclines», «trastuzumab», «chemotherapy»; biomarkers: «troponin», «troponin I», «troponin T», «high sensitive troponin»; complications of chemotherapy: "cardiotoxicity", studies: "controlled trial", "randomized controlled trial", "controlled clinical trial", "clinical trial". The selection of studies was carried out by the triangulation method. In total, the review included full-text 27 studies that completely met the search criteria. The list of references also contains researches that did not meet the search criteria, but illustrating the relevance of the topic.
Results. An increase in troponin levels may signify the development of cardiac dysfunction with a poor prognosis, especially if troponin levels continue to rise. The increase in the hs-troponin and the integral of the increase are more reliable predictors than the absolute value of troponin.
Сonclusions. Breast cancer patients receiving anthracyclines and subsequent targeted chimiotherapy have the highest risk of cardiotoxic complications. Troponin level monitoring has predictive potential and should be considered to all patients receiving chemotherapy. Troponin and the combination of several markers may turn out to be more sensitive in predicting cardiotoxicity in patients treated with anthracyclines and trastuzumab.
Number of Views: 300
Category of articles:
Reviews
Bibliography link
Tlegenova Zh.Sh., Zholdin B.K., Gendlin G.E., Balmagambetova S.K., Kurmanalina G.L., Talipova I.Zh. The Troponin prognostic capability in diagnosing cardiotoxicity during chemotherapy with anthracyclines and monoclonal antibodies in breast cancer patients // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 5, pp. 132-148. doi 10.34689/SH.2021.23.5.016Related publications:
CURRENT STATE OF DERMATOPHYTE RESISTANCE TO ANTIMYCOTIC AGENTS
THE ROLE OF BIOMEDICAL INFORMATICS IN THE STUDY OF BRONCHOPULMONARY DYSPLASIA
THE IMPORTANCE OF VISUAL SCREENING FOR LUNG CANCER
DIAGNOSIS AND TREATMENT OF KIDNEY TRANSPLANT REJECTION: A LITERATURE REVIEW.
COMPARATIVE CHARACTERISTICS OF BREAST RECONSTRUCTION METHODS. LITERATURE REVIEW